文献速递艾滋病与性传播感染

急性HIV感染期启动抗逆转录病毒治疗可正常化脑脊液免疫激活标志物但血浆未恢复

Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma.
PubMed 文献 · J Infect Dis · 2019-01-01

本研究基于RV254/SEARCH010队列,比较急性HIV感染者启动抗逆转录病毒治疗(ART)前后脑脊液和血浆免疫激活标志物变化。结果显示治疗24和96周后脑脊液所有标志物均正常化,而血浆多个标志物仍持续升高(P<.001)。提示急性期启动ART对中枢神经系统与血液免疫激活的影响存在差异。

要点

  • 急性HIV感染期启动ART后脑脊液免疫激活标志物在24和96周均正常化。
  • 血浆中多个免疫激活标志物在96周时仍持续升高(P<.001)。
  • ART加用马拉韦罗和雷特格韦方案与部分血浆标志物水平较低相关。

核心结论

  • 急性HIV感染期启动ART可使脑脊液炎症标志物恢复正常并维持至96周,但血浆标志物未恢复正常。

研究设计与样本

  • RV254/SEARCH010研究队列分析,急性HIV感染者在启动ART前及治疗第24、96周采集脑脊液(n=89)和血浆(n=146)样本,并与18名健康未感染对照比较。

主要发现

  • 治疗24和96周后,急性HIV感染组脑脊液所有标志物水平正常化,而血浆多个标志物仍升高(P<.001)。
  • 接受ART-plus方案者在第24周血浆CCL2中位数更低,第96周血浆新蝶呤水平更低。

关键数值与推荐

  • 多数参与者(64.4%)接受标准ART方案,部分(34.7%)在前24周加用马拉韦罗和雷特格韦(ART-plus)。
  • 脑脊液和血浆标志物包括新蝶呤、CXCL10、CCL2和白细胞介素6(IL-6)。

临床怎么用

  • 急性HIV感染期启动ART可能有助于中枢神经系统免疫激活的正常化,但血浆免疫激活持续存在,提示需关注全身炎症管理。

局限性

  • 急性HIV感染组样本量有限(脑脊液n=89,血浆n=146),对照组仅18人。
  • ART方案不完全统一,多数为标准ART,部分为ART-plus,可能影响标志物比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic immune activation in the blood and central nervous system is a consequence of human immunodeficiency virus (HIV) infection that contributes to disease morbidity and can occur despite virally suppressive antiretroviral therapy (ART). The trajectory of HIV-related inflammation may vary with the timing of ART initiation. We examined immune activation markers in cerebrospinal fluid (CSF) and blood specimens collected over 96 weeks from participants who initiated ART during acute HIV infection (AHI). METHODS: RV254/SEARCH010 study participants with AHI underwent CSF (n = 89) and plasma (n = 146) sampling before initiating ART and at weeks 24 and 96 of treatment. A majority participants (64.4%) received a standard ART regimen (hereafter, "standard ART"), with some (34.7%) also receiving maraviroc and raltegravir for the first 24 weeks (hereafter, "ART plus"). We compared neopterin, CXCL10, CCL2, and interleukin 6 (IL-6) levels in the AHI group to those in 18 healthy, uninfected controls. RESULTS: Following 24 and 96 weeks of treatment, levels of all CSF markers normalized while levels of several plasma markers remained elevated in the AHI group (P < .001). Participants receiving the ART-plus regimen had lower median plasma CCL2 levels at week 24 and lower plasma neopterin levels at week 96. CONCLUSIONS: ART initiation during AHI differentially impacts the brain compartment, with markers of inflammation returning to normal levels in the CSF, where they were sustained at week 96, but not in plasma.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hellmuth J, Slike BM, Sacdalan C, et al. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma. J Infect Dis. 2019. PMID: 30668739. doi:10.1093/infdis/jiz030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。